# Australian Radiation Protection and Nuclear Safety Agency

Entity Resources and  
Planned Performance

# Australian Radiation Protection and Nuclear Safety Agency

[Section 1: Entity Overview and Resources 228](#_Toc479061222)

[1.1 Strategic Direction Statement 228](#_Toc479061223)

[1.2 Entity Resource Statement 229](#_Toc479061224)

[1.3 Budget Measures 230](#_Toc479061225)

[Section 2: Outcomes and Planned Performance 231](#_Toc479061226)

[2.1 Budgeted Expenses and Performance 231](#_Toc479061227)

[Section 3: Budgeted Financial Statements 237](#_Toc479061228)

[3.1 Budgeted Financial Statements 237](#_Toc479061229)

[3.2 Budgeted Financial Statements Tables 238](#_Toc479061230)

## Section 1: Entity Overview and Resources

### 1.1 Strategic Direction Statement[[1]](#footnote-1)

The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA), on behalf of the Australian Government, aims to protect the Australian people and the environment from the harmful effects of radiation.

ARPANSA provides advice and services to the Australian community on radiation protection, nuclear safety, security, and medical exposures to radiation, including related research. It promotes national uniformity of radiation protection and nuclear safety policy and practices across the Commonwealth and States and Territories. It also independently regulates the radiation sources, radiation facilities and nuclear installations of Commonwealth entities and contractors.

ARPANSA’s regulatory and advisory frameworks are based on evidence regarding levels of ionising and non-ionising[[2]](#footnote-2) radiation in the environment and the effect on human and environmental health and wellbeing.

In 2017-18, ARPANSA will continue to refine its risk-informed approach to effective regulation of radiation and nuclear facilities and practices, while striving to reduce the regulatory burden, through activities such as benchmarking Australia’s radiation and nuclear safety framework against the International Atomic Energy Agency safety standards.

ARPANSA will also assess exposure to the public, workers and the environment to ionising and non-ionising radiation through monitoring and publishing UV data and radiation doses to exposed workers.

For the purpose of radiation protection of patients, ARPANSA will expand the audit service for linear accelerators used in radiation therapy and continue the establishment of diagnostic reference levels for medical imaging.

The role and functions of ARPANSA are set out in the *Australian Radiation Protection and Nuclear Safety Act 1998*. ARPANSA is a Non-corporate Commonwealth Entity under the *Public Governance, Performance and Accountability Act 2013*.

### 1.2 Entity Resource Statement

Table 1.1 shows the total funding from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (Government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity’s operations) classification.

For more detailed information on special accounts and special appropriations, please refer to *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (i.e. appropriations/cash available) basis, whilst the ‘Budgeted expenses by outcome’ tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis.

Table 1.1: ARPANSA Resource Statement – Budget Estimates for 2017-18 as at Budget May 2017

|  |  |  |
| --- | --- | --- |
|  | **2016-17 Estimated actual** $'000 | **2017-18 Estimate** $'000 |
| **DEPARTMENTAL** |  |  |
| Prior year appropriation available | 1,210 | 1,210 |
| **Annual appropriations** |  |  |
| Ordinary annual services (a) |  |  |
| Departmental appropriation | 13,049 | 12,839 |
| s74 retained revenue receipts (b) | 10,654 | 9,712 |
| Departmental capital budget (c) | 2,124 | 1,955 |
| Other services (d) |  |  |
| Equity injection | - | 5,000 |
| **Total departmental annual appropriations** | **25,827** | **29,506** |
| **Special Accounts (e)** |  |  |
| Appropriation receipts | 15,173 | 19,794 |
| Non-appropriation receipts | 10,654 | 9,712 |
| **Total special account** | **25,827** | **29,506** |
| Less appropriations drawn from annual or special appropriations above and credited to Special Accounts (f) | (25,827) | (29,506) |
| **Total departmental resourcing** | **27,037** | **30,716** |
| **Total resourcing for ARPANSA** | **27,037** | **30,716** |
|  |  |  |
|  | **2016-17** | **2017-18** |
| **Average staffing level (number)** | 131 | 130 |

All figures are GST exclusive.

(a) Appropriation Bill (No. 1) 2017-18.

(b) Estimated retained revenue receipts under section 74 of the PGPA Act 2013.

(c) Departmental Capital Budgets (DCB) are not separately identified in Appropriation Bill (No. 1) and form part of ordinary annual services items. Refer to Table 3.5 for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

(d) Appropriation Bill (No. 2) 2017-18.

(e) For further information on special appropriations and special accounts, please refer to *Budget Paper No. 4 - Agency Resourcing*. Also see Table 2.1.1 for further information on outcome and program expenses broken down by various funding sources, e.g. annual appropriations, special appropriations and special accounts.

(f) Appropriation receipts included above.

### 1.3 Budget Measures

This section is not applicable to ARPANSA

## Section 2: Outcomes and Planned Performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which Government entities achieve the intended results of their outcome statements. Entities are required to identify the programs which contribute to Government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

Note:

Performance reporting requirements in the Portfolio Budget Statements are part of the Enhanced Commonwealth Performance Framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance criteria described in Portfolio Budget Statements will be read with broader information provided in an entity’s corporate plans and annual performance statements – included in Annual Reports – to provide an entity’s complete performance story.

ARPANSA’s most recent corporate plan is available at: www.arpansa.gov.au/AboutUs/Corporate/corplan2016-20.cfm

ARPANSA’s most recent annual performance statement is available at: www.arpansa.gov.au/AboutUs/corporate/ar1516/1516home.cfm

### 2.1 Budgeted Expenses and Performance

**Outcome 1**

Protection of people and the environment through radiation protection and nuclear safety research, policy, advice, codes, standards, services and regulation

#### Program Contributing to Outcome 1

Program 1.1: Radiation Protection and Nuclear Safety

#### Linked Programs

| Other Commonwealth entities that contribute to Outcome 1 |
| --- |
| Department of Health  Program 5.1: Protect the Health and Safety of the Community Through Regulation  The Department of Health has strategic regulatory policy and national leadership responsibility for radiation protection and nuclear safety with particular regard to the regulatory framework. This includes best practice for health technologies related to radiation and nuclear safety. |

#### Budgeted Expenses for ARPANSA

Table 2.1.1 shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by administered and departmental funding sources.

Table 2.1.1: Budgeted Expenses for ARPANSA

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2016-17 Estimated actual** $'000 | **2017-18 Budget** $'000 | **2018-19 Forward Year 1** $'000 | **2019-20 Forward Year 2** $'000 | **2020-21 Forward Year 3** $'000 |
| **Program 1.1: Radiation Protection and Nuclear Safety** | | | | | |
| Departmental expenses |  |  |  |  |  |
| Ordinary annual services (a) | 13,049 | 12,839 | 12,729 | 12,729 | 12,791 |
| Special Accounts | 10,654 | 9,712 | 9,823 | 9,937 | 10,046 |
| Expenses not requiring appropriation | | 2,570 | 2,570 | 2,570 | 2,570 |
| in the Budget year (b) | 2,570 |
| Operating deficit (surplus) |  |  |  |  |  |
| **Total for Program 1.1** | **26,273** | **25,121** | **25,122** | **25,236** | **25,407** |
| **Total expenses for Outcome 1** | **26,273** | **25,121** | **25,122** | **25,236** | **25,407** |
|  |  |  |  |  |  |
|  | **2016-17** | **2017-18** |  |  |  |
| **Average staffing level (number)** | 131 | 130 |  |  |  |

(a) Appropriation (Bill No. 1) 2017-18.

(b) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expense and audit fees.

#### Planned Performance for ARPANSA

Table 2.1.2 below details the performance criteria for the program associated with Outcome 1.[[3]](#footnote-3) It also summarises how the program is delivered and where 2017-18 Budget measures have materially changed the program.

Table 2.1.2: Performance Criteria for ARPANSA

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Purpose | | | | | | | | |
| The Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) is the Australian Government’s primary authority on radiation protection and nuclear safety. Our purpose is to protect the Australian people and the environment from the harmful effects of radiation, through research, policy, advice, codes, standards, services and regulation. | | | | | | | | |
| Outcome 1 | | | | | | | | |
| Protection of people and the environment through radiation protection and nuclear safety research, policy, advice, codes, standards, services and regulation | | | | | | | | |
| Program 1.1: Radiation Protection and Nuclear Safety | | | | | | | | |
| The Australian Government, through ARPANSA, aims to protect the Australian people and the environment from the harmful effects of radiation. Scientific knowledge and international best practice is applied to promote awareness of the effects of radiation, and a nationally uniform approach to radiation protection of people (the public, workers and patients undergoing medical procedures using radiation) and the environment.  ARPANSA regulates the use of radiation sources, facilities and nuclear installations controlled by the Australian Government. It provides expert support to national, regional and international arrangements for safety, security and responses to nuclear and radiological emergencies. | | | | | | | | |
| Delivery | | | | | | | | |
| A. Protecting the public, workers and the environment from radiation exposure   * Evaluate radiation dose trends to workers to inform protective actions. * Provide advice to the Government and the public on radiation protection and nuclear safety.   B. Promoting radiological and nuclear safety and security, and emergency preparedness   * Support national and regional arrangements for preventing accidents and security events that may lead to radiation exposure. * Maintain effective emergency response systems that protect the Australian community in the case of a radiological or nuclear event.   C. Promoting the safe and effective use of ionising radiation in medicine   * Provide auditing and calibration services to clinics to support radiation protection of patients in diagnosis and therapy. * Survey clinics and disseminate information on diagnostic exposure levels, with the aim of optimising patient protection.   D. Ensuring risk-informed and efficient regulation   * Conduct self-assessment and external reviews to improve ARPANSA’s regulatory processes for the benefit of licence holders, applicants and the Australian community. * Interact with State and Territory jurisdictions to promote national uniformity in radiation protection policies and practices. | | | | | | | | |
| Performance criteria | | | | | | | | |
| A. Protecting the public, workers and the environment from radiation exposure | | | | | | | | |
| Monitor radiation doses to occupationally exposed workers.[[4]](#footnote-4) | | | | | | | | |
| 2016-17 Estimated result | | 2017-18 Target | | | | | 2018-19 (& beyond) Target | |
| Achieved.  Australian National Radiation Dose Register Annual Newsletter published September 2016.[[5]](#footnote-5) | | Annual reporting of trend in radiation doses received by workers, determined from quantitative dose measurement, provides evidence of optimisation of radiation protection. | | | | | As per 2017-18. | |
| UV monitoring network data available to the public.[[6]](#footnote-6) | | | | | | | | |
| 2016-17 Estimated result | 2017-18 Target | | | 2018-19 Target | 2019-20 Target | | | 2020-21 Target |
| N/A[[7]](#footnote-7) | >95% | | | >95% | >95% | | | >95% |
| B. Promoting radiological and nuclear safety and security, and emergency preparedness | | | | | | | | |
| ARPANSA is prepared for a radiological or nuclear incident or emergency. | | | | | | | | |
| 2016-17 Estimated result | | | 2017-18 Target | | | 2018-19 (& beyond) Target | | |
| Target on track to be met. | | | Emergency preparedness and response systems for field, network and laboratory measurements, and information management and decision support systems are available, calibrated, tested and aligned with national planning. | | | As per 2017-18. | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| C. Promoting the safe and effective use of ionising radiation in medicine | | | | |
| Number of Diagnostic Reference Level surveys per annual survey period.[[8]](#footnote-8) | | | | |
| 2016-17 Estimated result | 2017-18 Target | 2018-19 Target | 2019-20 Target | 2020-21 Target |
| 1,507 | >1,200 | >1,400 | >1,600 | >1,600 |
| Percentage of Australian radiotherapy providers subscribing to the national dosimetric auditing program provided by the Australian Clinical Dosimetry Service. | | | | |
| 2016-17 Estimated result | 2017-18 Target | 2018-19 Target | 2019-20 Target | 2020-21 Target |
| >50% | >50% | >60% | >70% | >70% |
| Percentage of Australian radiotherapy providers covered by ARPANSA dose calibration services. | | | | |
| 2016-17 Estimated result | 2017-18 Target | 2018-19 Target | 2019-20 Target | 2020-21 Target |
| >70% | >70% | >70% | >70% | >80% |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| D. Ensuring risk-informed and efficient regulation | | | | | | |
| Monitor doses to radiation workers at licensed Commonwealth facilities and influence the doses in a downward manner. | | | | | | |
| 2016-17 Estimated result | | 2017-18 Target | | | 2018-19 (& beyond) Target | |
| N/A[[9]](#footnote-9) | | The radiation doses of the 100 most exposed workers at licensed Commonwealth facilities trend downwards over time. | | | As per 2017-18. | |
| Benchmark Australia’s radiation and nuclear safety framework against the International Atomic Energy Agency (IAEA) safety requirements, by means of an Integrated Regulatory Review Service (IRRS) mission to Australia. | | | | | | |
| 2016-17 Estimated result | | 2017-18 Target | | | 2018-19 (& beyond) Target | |
| N/A[[10]](#footnote-10) | | Complete self-assessment of ARPANSA’s and participating States’ and Territories’ framework for radiation and nuclear safety, prepare draft action plan. | | | Receive Integrated Regulatory Review Service mission coordinated by International Atomic Energy Agency, finalise action plan and commence implementation. | |
| Inspections are conducted in accordance with established inspection schedule. | | | | | | |
| 2016-17 Estimated result | 2017-18 Target | | 2018-19 Target | 2019-20 Target | | 2020-21 Target |
| >85% | >85% | | >85% | >85% | | >85% |
| Material changes to Program 1.1 resulting from the following measures:   * There are no material changes to Program 1.1 resulting from measures. | | | | | | |

## Section 3: Budgeted Financial Statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2017-18 Budget year, including the impact of Budget measures and resourcing on financial statements.

### 3.1 Budgeted Financial Statements

#### 3.1.1 Differences Between Entity Resourcing and Financial Statements

This section is not applicable to ARPANSA.

#### 3.1.2 Explanatory Notes and Analysis of Budgeted Financial Statements

##### Departmental Resources

###### Comprehensive Income Statement

ARPANSA’s own sourced income is derived from the sale of scientific services such as the Personal Radiation Monitoring Service, the Comprehensive Nuclear‑Test-Ban Treaty (CTBT) Organisation contracts to operate and maintain monitoring stations, and licence application fees and annual charges associated with ARPANSA’s regulatory activities.

For the 2017-18 and forward years ARPANSA is budgeting for a break even result after adjustment for unfunded depreciation and amortisation expenses.

###### Balance Sheet

ARPANSA’s total asset and liabilities are expected to remain stable over the forward years.

###### Cash Flow

Cash flows are consistent with projected income and expense, capital injections from Government and investments in property, plant and equipment.

### 3.2 Budgeted Financial Statements Tables

Table 3.1: Comprehensive Income Statement (showing net cost of services for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2016-17 Estimated actual** $'000 | **2017-18 Budget**   $'000 | **2018-19 Forward estimate** $'000 | **2019-20 Forward estimate** $'000 | **2020-21 Forward estimate** $'000 |
| **EXPENSES** |  |  |  |  |  |
| Employee benefits | 16,502 | 16,498 | 16,494 | 16,490 | 16,490 |
| Supplier expenses | 7,201 | 6,053 | 6,058 | 6,176 | 6,347 |
| Depreciation and amortisation | 2,570 | 2,570 | 2,570 | 2,570 | 2,570 |
| **Total expenses** | **26,273** | **25,121** | **25,122** | **25,236** | **25,407** |
| **LESS:** |  |  |  |  |  |
| **OWN-SOURCE INCOME** |  |  |  |  |  |
| **Revenue** |  |  |  |  |  |
| Sale of goods and rendering of services | 6,325 | 5,275 | 5,275 | 5,275 | 5,275 |
| Other revenue | 4,329 | 4,437 | 4,548 | 4,662 | 4,771 |
| **Total revenue** | **10,654** | **9,712** | **9,823** | **9,937** | **10,046** |
| **Total own-source income** | **10,654** | **9,712** | **9,823** | **9,937** | **10,046** |
| **Net cost of (contribution by) services** | **15,619** | **15,409** | **15,299** | **15,299** | **15,361** |
| Revenue from Government | 13,049 | 12,839 | 12,729 | 12,729 | 12,791 |
| **Surplus (deficit)** | **(2,570)** | **(2,570)** | **(2,570)** | **(2,570)** | **(2,570)** |
| **Surplus (deficit) attributable to the Australian Government** | **(2,570)** | **(2,570)** | **(2,570)** | **(2,570)** | **(2,570)** |
| **OTHER COMPREHENSIVE INCOME** |  |  |  |  |  |
| Changes in asset revaluation reserves | - | - | - | - | - |
| **Total other comprehensive income** | **-** | **-** | **-** | **-** | **-** |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(2,570)** | **(2,570)** | **(2,570)** | **(2,570)** | **(2,570)** |
|  |  |  |  |  |  |
| **Note: Reconciliation of comprehensive income attributable to the agency** | | | | | |
|  | **2016-17** $'000 | **2017-18** $'000 | **2018-19** $'000 | **2019-20** $'000 | **2020-21** $'000 |
| **Total comprehensive income (loss) attributable to the Australian Government** | **(2,570)** | **(2,570)** | **(2,570)** | **(2,570)** | **(2,570)** |
| plus non-appropriated expenses depreciation and amortisation expenses | 2,570 | 2,570 | 2,570 | 2,570 | 2,570 |
| **Total comprehensive income (loss) attributable to the agency** | **-** | **-** | **-** | **-** | **-** |

Table 3.2: Budgeted Departmental Balance Sheet (as at 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2016-17 Estimated actual** $'000 | **2017-18 Budget**   $'000 | **2018-19 Forward estimate** $'000 | **2019-20 Forward estimate** $'000 | **2020-21 Forward estimate** $'000 |
| **ASSETS** |  |  |  |  |  |
| **Financial assets** |  |  |  |  |  |
| Cash and cash equivalents | 1,210 | 1,210 | 1,210 | 1,210 | 1,210 |
| Receivables | 933 | 933 | 933 | 933 | 933 |
| Accrued revenue | 83 | 83 | 83 | 83 | 83 |
| **Total financial assets** | **2,226** | **2,226** | **2,226** | **2,226** | **2,226** |
| **Non-financial assets** |  |  |  |  |  |
| Land and buildings | 24,441 | 24,223 | 24,005 | 23,787 | 23,442 |
| Property, plant and equipment | 6,526 | 10,894 | 10,250 | 9,612 | 9,434 |
| Inventories | 1,533 | 1,533 | 1,533 | 1,533 | 1,533 |
| Intangibles | 1,248 | 1,483 | 1,718 | 1,953 | 1,941 |
| Other | 436 | 436 | 436 | 436 | 436 |
| **Total non-financial assets** | **34,184** | **38,569** | **37,942** | **37,321** | **36,786** |
| **Total assets** | **36,410** | **40,795** | **40,168** | **39,547** | **39,012** |
| **LIABILITIES** |  |  |  |  |  |
| **Payables** |  |  |  |  |  |
| Suppliers | - | - | - | - | - |
| Other payables | 1,159 | 1,159 | 1,159 | 1,159 | 1,159 |
| **Total payables** | **1,159** | **1,159** | **1,159** | **1,159** | **1,159** |
| **Provisions** |  |  |  |  |  |
| Employees | 4,545 | 4,545 | 4,545 | 4,545 | 4,545 |
| **Total provisions** | **4,545** | **4,545** | **4,545** | **4,545** | **4,545** |
| **Total liabilities** | **5,704** | **5,704** | **5,704** | **5,704** | **5,704** |
| **Net assets** | **30,706** | **35,091** | **34,464** | **33,843** | **33,308** |
| **EQUITY** |  |  |  |  |  |
| Contributed equity | 21,606 | 28,561 | 30,504 | 32,453 | 34,488 |
| Reserves | 14,609 | 14,609 | 14,609 | 14,609 | 14,609 |
| Retained surpluses (accumulated deficits) | (5,509) | (8,079) | (10,649) | (13,219) | (15,789) |
| **Total equity** | **30,706** | **35,091** | **34,464** | **33,843** | **33,308** |

Table 3.3: Departmental Statement of Changes in Equity – Summary of Movement (Budget year 2017-18)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Retained earnings**   $'000 | **Asset revaluation reserve**  $'000 | **Contributed equity/capital**   $'000 | **Total  equity**   $'000 |
| **Opening balance as at 1 July 2017** |  |  |  |  |
| Balance carried forward from previous period | (5,509) | 14,609 | 21,606 | **30,706** |
| Surplus (deficit) for the period | (2,570) | - | - | **(2,570)** |
| Capital budget - Bill 1 (DCB) | - | - | 1,955 | **1,955** |
| Equity injection - appropriation | - | - | 5,000 | **5,000** |
| **Estimated closing balance as at 30 June 2018** | **(8,079)** | **14,609** | **28,561** | **35,091** |

DCB = Departmental Capital Budget.

Table 3.4: Budgeted Departmental Statement of Cash Flows (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2016-17 Estimated actual** $'000 | **2017-18 Budget**   $'000 | **2018-19 Forward estimate** $'000 | **2019-20 Forward estimate** $'000 | **2020-21 Forward estimate** $'000 |
| **OPERATING ACTIVITIES** |  |  |  |  |  |
| **Cash received** |  |  |  |  |  |
| Goods and services | 5,840 | 4,790 | 4,790 | 4,790 | 4,796 |
| Appropriations | 13,049 | 12,839 | 12,729 | 12,729 | 12,791 |
| Net GST received | 485 | 485 | 485 | 485 | 479 |
| Other cash received | 4,329 | 4,437 | 4,548 | 4,662 | 4,771 |
| **Total cash received** | **23,703** | **22,551** | **22,552** | **22,666** | **22,837** |
| **Cash used** |  |  |  |  |  |
| Employees | 16,503 | 16,498 | 16,494 | 16,490 | 16,490 |
| Suppliers | 6,499 | 5,370 | 5,375 | 5,493 | 5,664 |
| Net GST paid | 701 | 683 | 683 | 683 | 683 |
| **Total cash used** | **23,703** | **22,551** | **22,552** | **22,666** | **22,837** |
| **Net cash from (or used by) operating activities** | **-** | **-** | **-** | **-** | **-** |
| **INVESTING ACTIVITIES** |  |  |  |  |  |
| **Cash used** |  |  |  |  |  |
| Purchase of property, plant and equipment | 2,124 | 6,955 | 1,943 | 1,949 | 2,035 |
| **Total cash used** | **2,124** | **6,955** | **1,943** | **1,949** | **2,035** |
| **Net cash from (or used by) investing activities** | **(2,124)** | **(6,955)** | **(1,943)** | **(1,949)** | **(2,035)** |
| **FINANCING ACTIVITIES** |  |  |  |  |  |
| **Cash received** |  |  |  |  |  |
| Capital budget - Bill 1 (DCB) | 2,124 | 6,955 | 1,943 | 1,949 | 2,035 |
| **Total cash received** | **2,124** | **6,955** | **1,943** | **1,949** | **2,035** |
| **Net cash from (or used by) financing activities** | **2,124** | **6,955** | **1,943** | **1,949** | **2,035** |
| **Net increase (or decrease) in cash held** | **-** | **-** | **-** | **-** | **-** |
| Cash and cash equivalents at the beginning of the reporting period | 1,210 | 1,210 | 1,210 | 1,210 | 1,210 |
| **Cash and cash equivalents at the end of the reporting period** | **1,210** | **1,210** | **1,210** | **1,210** | **1,210** |

DCB = Departmental Capital Budget.

Table 3.5: Departmental Capital Budget Statement (for the period ended 30 June)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **2016-17 Estimated actual** $'000 | **2017-18 Budget**   $'000 | **2018-19 Forward estimate** $'000 | **2019-20 Forward estimate** $'000 | **2020-21 Forward estimate** $'000 |
| **CAPITAL APPROPRIATIONS** |  |  |  |  |  |
| Capital budget - Bill 1 (DCB) | 2,124 | 1,955 | 1,943 | 1,949 | 2,035 |
| Equity injections - Bill 2 | - | 5,000 | - | - | - |
| **Total capital appropriations** | **2,124** | **6,955** | **1,943** | **1,949** | **2,035** |
| **Total new capital appropriations represented by:** |  |  |  |  |  |
| Purchase of non-financial assets | 2,124 | 6,955 | 1,943 | 1,949 | 2,035 |
| **Total items** | **2,124** | **6,955** | **1,943** | **1,949** | **2,035** |
| **PURCHASE OF NON-FINANCIAL ASSETS** |  |  |  |  |  |
| Funded by capital appropriation | - | 5,000 | - | - | - |
| Funded by capital appropriation - DCB (a) | 2,124 | 1,955 | 1,943 | 1,949 | 2,035 |
| **Total acquisitions of non‑financial assets** | **2,124** | **6,955** | **1,943** | **1,949** | **2,035** |
| **RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE** |  |  |  |  |  |
| Total purchases | 2,124 | 6,955 | 1,943 | 1,949 | 2,035 |
| **Total cash used to acquire assets** | **2,124** | **6,955** | **1,943** | **1,949** | **2,035** |

(a) Does not include annual finance lease costs. Includes purchases from current and previous years' Departmental Capital Budget (DCB).

Table 3.6: Statement of Asset Movements (Budget year 2017‑18)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Land** $'000 | **Buildings** $'000 | **Other property, plant and equipment** $'000 | **Intangibles**     $'000 | **Total** $'000 |
| **As at 1 July 2017** |  |  |  |  |  |
| Gross book value | 7,500 | 24,333 | 18,884 | 4,133 | **54,850** |
| Accumulated depreciation/ amortisation and impairment | - | (7,392) | (12,358) | (2,885) | **(22,635)** |
| **Opening net book balance** | **7,500** | **16,941** | **6,526** | **1,248** | **32,215** |
| **CAPITAL ASSET ADDITIONS** |  |  |  |  |  |
| **Estimated expenditure on new or replacement assets** |  |  |  |  |  |
| By purchase - appropriation ordinary annual services | - | 727 | 5,781 | 447 | **6,955** |
| **Total additions** | **-** | **727** | **5,781** | **447** | **6,955** |
| **Other movements** |  |  |  |  |  |
| Depreciation/amortisation expense | - | (945) | (1,413) | (212) | **(2,570)** |
| **Total other movements** | **-** | **(945)** | **(1,413)** | **(212)** | **(2,570)** |
| **As at 30 June 2018** |  |  |  |  |  |
| Gross book value | 7,500 | 25,060 | 24,665 | 4,580 | **61,805** |
| Accumulated depreciation/ amortisation and impairment | - | (8,337) | (13,771) | (3,097) | **(25,205)** |
| **Closing net book balance** | **7,500** | **16,723** | **10,894** | **1,483** | **36,600** |

1. For more information about the strategic direction of ARPANSA, refer to the current corporate plan, available at: www.arpansa.gov.au/AboutUs/Corporate/corplan.cfm [↑](#footnote-ref-1)
2. Ionising radiation from radioactive substances or X-ray equipment can produce ionisation in matter. It has sufficient energy to damage the heredity material in cells (DNA). Non-ionising radiation such as UV radiation from the sun or from emitters of radiofrequency radiation does not produce ionisation, but may still cause health effects. [↑](#footnote-ref-2)
3. Progress against the performance criteria published in the *2016-17 Portfolio Budget Statements* will be reported in the 2016-17 ARPANSA Annual Report. [↑](#footnote-ref-3)
4. This measure refers to dose records captured in the Australian National Radiation Dose Register. [↑](#footnote-ref-4)
5. Australian National Radiation Dose Register Annual Newsletter can be found at: www.arpansa.gov.au/pubs/Services/ANRDR/ANRDR\_in\_Review\_Sep16.pdf [↑](#footnote-ref-5)
6. ARPANSA has a network of UV detectors in cities around Australia. The UV data is collected continuously by detectors that respond to UV in a manner similar to human skin. Data is used to provide real-time and historical UV levels to inform the public when protective measures should be taken outdoors. Data is available at: www.arpansa.gov.au/uvindex/index.cfm [↑](#footnote-ref-6)
7. This is a new performance criterion for 2017-18, therefore there is no estimated result for 2016-17. [↑](#footnote-ref-7)
8. The Australian National Diagnostic Reference Level Service provides individual facilities with a tool for comparing their representative medical imaging patient dose metrics with the National Diagnostic Reference Levels (DRLs). The data from DRL surveys, collected over a calendar year from individual facilities, is collated and used to establish and update National DRLs for common diagnostic imaging procedures. [↑](#footnote-ref-8)
9. This is a new performance criterion for 2017-18, therefore there is no estimated result for 2016-17. [↑](#footnote-ref-9)
10. Ibid. [↑](#footnote-ref-10)